References
- Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin N Am 2003; 32: 967–95
- Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004; 126: 1550–60
- Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661–5
- Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7: 460–5
- Striz I, Trebichavsky I. Calprotectin: a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004; 53: 245–53
- Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628–37
- Bunn SK, Bisset WM, Main MJC, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14–22
- Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000; 356: 1783
- Bunn SK, Bisset WM, Main MJC, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171–7
- Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T, et al. Regulation of S100A8 by glucocorticoids. J Immunol 2005; 174: 2318–26
- Gebhardt C, Breitenbach U, Tuckermann JP, Dittrich BT, Richter KH, Angel P. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 2002; 20: 4266–76
- Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017–20
- Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a paediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439–47
- Lorentzon Fagerberg U, Lööf L, Myrdal U, Hansson L-O, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450–5
- Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506–13
- Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Gut 2001; 49: 402–8
- Escher JC, Taminiau JAJM, Nieuwenhuis EES, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003; 9: 34–58
- Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1996; 22: 373–9
- Arnott IDR, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease. Aliment Pharmacol Ther 2002; 16: 857–67
- Göke MN, Schneider M, Beil W, Manns MB. Differential glucocorticoid effects on repair mechanisms and NF-?B activity in the intestinal epithelium. Regul Pept 2002; 105: 203–14
- Gremse DA, Crissinger KD. Ulcerative colitis in children: medical management. Paediatr Drugs 2002; 4: 807–15